- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00016861
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
Pediatric Phase I and Pharmacokinetic Study of Irinotecan
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or progressive solid tumors.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan in children with refractory or progressive solid tumors.
- Determine the pharmacokinetics of this drug and its metabolites (SN-38, SN-38G, and APC) administered with and without concurrent anticonvulsants in this patient population.
- Determine the benefit this drug offers this patient population.
OUTLINE: This is a dose-escalation, multicenter study. Patients are accrued into stratum 1 initially and into stratum 2 if stratum 1 closes due to dose-limiting toxicity of myelosuppression or diarrhea. Patients on anticonvulsants will be accrued into stratum 3 and must meet the eligibility criteria for the stratum that is open (stratum 1 or stratum 2). (Stratum 1 closed as of 2002-09-15).
Patients receive irinotecan IV over 90 minutes weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) with and without anticonvulsants is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 6 months for 4 years and then annually thereafter.
PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.
Studietyp
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030-2399
- Texas Children's Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed solid tumor refractory to standard therapy or for which no known effective therapy exists
Brain tumors eligible
- Histologic verification waived for brain stem gliomas
- Evaluable disease
- No bone marrow involvement
PATIENT CHARACTERISTICS:
Age:
- 1 to 21
Performance status:
- Karnofsky 50-100% (over age 10)
- Lansky 50-100% (age 10 and under)
Life expectancy:
- At least 8 weeks
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL
Hepatic:
- Bilirubin less than 1.5 mg/dL
- SGPT less than 5 times normal
Renal:
- Creatinine normal OR
- Glomerular filtration rate at least 70 mL/min
Other:
- No uncontrolled infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 6 months since prior autologous bone marrow transplantation (BMT) (not including stem cell rescue after high-dose chemotherapy)
- At least 1 week since prior growth factors
- No prior BMT with total body irradiation (stratum I)
- No prior BMT with or without total body irradiation (stratum 2)
- No prior allogeneic BMT (all strata)
- No concurrent sargramostim (GM-CSF)
- No other concurrent prophylactic growth factor support during the first course of therapy
Chemotherapy:
- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
- No prior irinotecan
- No more than 2 prior multi-agent chemotherapy regimens (stratum 2)
- No other concurrent chemotherapy
Endocrine therapy:
- Concurrent dexamethasone allowed if on stable or decreasing dose for at least 2 weeks prior to study
Radiotherapy:
- At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- No prior central axis radiotherapy, pelvic radiotherapy, and/or total abdominal radiotherapy (stratum 2)
Surgery:
- Not specified
Other:
- Recovered from all prior therapy
- No other concurrent investigational agents
- Concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine) allowed if on stable dose for at least 2 weeks prior to study (stratum 3)
- Concurrent valproic acid allowed if combined with another enzyme inducing anticonvulsant drug (stratum 3)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Susan M. Blaney, MD, Texas Children's Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TCCC-H-6957
- CDR0000068568 (Registeridentifierare: PDQ (Physician Data Query))
- TCCC-GCRC-0654
- NCI-V01-1654
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på irinotekanhydroklorid
-
Shanghai Zhangjiang Biotechnology Limited CompanyShanghai Biomabs Pharmaceutical Co., Ltd.AvslutadMetastaserande kolorektal cancer
-
M.D. Anderson Cancer CenterIndragenMetastaserande icke-småcelligt lungkarcinom | Steg IVA lungcancer AJCC v8 | Steg IVB lungcancer AJCC v8 | Steg IV lungcancer AJCC v8
-
Boston Scientific CorporationBiocompatibles UK LtdAvslutadMetastaserande kolorektal cancerStorbritannien, Österrike, Frankrike
-
Centre Oscar LambretSFCEAvslutad
-
Generic Devices Consulting, Inc.Biocompatibles UK LtdAvslutadInoperabel metastaserande tjock- och ändtarmscancerFörenta staterna
-
New Mexico Cancer Care AllianceWyeth is now a wholly owned subsidiary of PfizerAvslutadSarkomFörenta staterna
-
Uppsala UniversityRekryteringKolorektal cancer | Peritoneala metastaserSverige
-
Enzon Pharmaceuticals, Inc.OkändMetastaserande kolorektal cancerFörenta staterna, Kanada, Israel, Nederländerna, Storbritannien
-
AbbVie (prior sponsor, Abbott)AvslutadFasta tumörerFörenta staterna
-
H. Lee Moffitt Cancer Center and Research InstituteAvslutadGliom | Astrocytom | OligodendrogliomFörenta staterna